RI-002

Phase 3Biologic

AADMA Biologics, Inc.

RI-002 is one of 17 biologic programs targeting Immunodeficiency Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immunodeficiency DiseaseActive, not recruiting

Immunodeficiency DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Immunodeficiency Disease

#DrugCompanyPhaseTrials

Famvir

Retrovir

Epivir

GGlaxo Dba Glaxosmithkline

Approved

—4

Sustiva

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Asceniv

1 6

HYQVIA

Takeda

Phase 3

1 7

TAK-881

Takeda

Phase 3

3 8

TAK-771

Takeda

Phase 3

2 9

Newgam

Octapharma

Phase 3

1 10

Octanorm

Octapharma

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Immunodeficiency Disease1 trial

Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)

Completed·AADMA Biologics, Inc.·Phase 3·NCT01814800·59 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RI-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RI-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RI-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ADMA Biologics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: AADMA Biologics, Inc.

RI-002

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Immunodeficiency Disease1 trial

References

Drug Info

Quick Facts

Related News